{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:16:29Z","timestamp":1794028589222,"version":"4.8.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.vaccine.2022.01.016","type":"journal-article","created":{"date-parts":[[2022,1,22]],"date-time":"2022-01-22T15:57:26Z","timestamp":1642867046000},"page":"1143-1151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Characterization of the cell-mediated immune response to Takeda\u2019s live-attenuated tetravalent dengue vaccine in adolescents participating in a phase 2 randomized controlled trial conducted in a dengue-endemic setting"],"prefix":"10.1016","volume":"40","author":[{"given":"Vianney","family":"Tricou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Gottardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Egan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Clement","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Leroux-Roels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"S\u00e1ez-Llorens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Borkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansi J.","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.01.016_b0005","unstructured":"World Health Organization. Dengue and severe dengue. Available at: http:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dengue-and-severe-dengue [accessed 22 September 2021]."},{"issue":"1","key":"10.1016\/j.vaccine.2022.01.016_b0010","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1473-3099(01)00171-2","article-title":"Dengue: an update","volume":"2","author":"Guzm\u00e1n","year":"2002","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2022.01.016_b0015","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s00705-013-1645-3","article-title":"Secondary infection as a risk factor for dengue hemorrhagic fever\/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection","volume":"158","author":"Guzman","year":"2013","journal-title":"Arch Virol"},{"issue":"6365","key":"10.1016\/j.vaccine.2022.01.016_b0020","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1126\/science.aan6836","article-title":"Antibody-dependent enhancement of severe dengue disease in humans","volume":"358","author":"Katzelnick","year":"2017","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.vaccine.2022.01.016_b0025","doi-asserted-by":"crossref","first-page":"725","DOI":"10.4269\/ajtmh.1999.61.725","article-title":"Common occurrence of concurrent infections by multiple dengue virus serotypes","volume":"61","author":"Beaty","year":"1999","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2022.01.016_b0030","first-page":"329","article-title":"Meeting of the Strategic Advisory Group of Experts on immunization, April 2018 \u2013 conclusions and recommendations","volume":"93","author":"World Health Organization","year":"2018","journal-title":"Wkly Epidemiol Rec"},{"issue":"5","key":"10.1016\/j.vaccine.2022.01.016_b0035","doi-asserted-by":"crossref","first-page":"e2243","DOI":"10.1371\/journal.pntd.0002243","article-title":"Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax)","volume":"7","author":"Huang","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2022.01.016_b0040","first-page":"35","author":"Yoksan","year":"1986","journal-title":"Commonwealth Scientific and Industrial Research Organization, Division of Tropical Animal Science and Queensland Institute of Medical Research"},{"issue":"21","key":"10.1016\/j.vaccine.2022.01.016_b0045","doi-asserted-by":"crossref","first-page":"11436","DOI":"10.1128\/JVI.77.21.11436-11447.2003","article-title":"Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development","volume":"77","author":"Huang","year":"2003","journal-title":"J Virol"},{"issue":"42","key":"10.1016\/j.vaccine.2022.01.016_b0050","doi-asserted-by":"crossref","first-page":"7251","DOI":"10.1016\/j.vaccine.2011.07.020","article-title":"Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever","volume":"29","author":"Osorio","year":"2011","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2022.01.016_b0055","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/infdis\/jiv179","article-title":"Safety and immunogenicity of a live attenuated tetravalent dengue vaccine candidate in flavivirus-naive adults: a randomized, double-blinded phase 1 clinical trial","volume":"212","author":"George","year":"2015","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2022.01.016_b0060","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1473-3099(14)70811-4","article-title":"Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study","volume":"14","author":"Osorio","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"46","key":"10.1016\/j.vaccine.2022.01.016_b0065","doi-asserted-by":"crossref","first-page":"6351","DOI":"10.1016\/j.vaccine.2015.09.008","article-title":"Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: a phase 1b randomized study","volume":"33","author":"Rupp","year":"2015","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2022.01.016_b0070","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1473-3099(17)30632-1","article-title":"Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2\u201317 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study","volume":"18","author":"S\u00e1ez-Llorens","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2022.01.016_b0075","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1473-3099(17)30166-4","article-title":"Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study","volume":"17","author":"S\u00e1ez-Llorens","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2022.01.016_b0080","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/infdis\/jiv762","article-title":"Safety and immunogenicity of a tetravalent dengue vaccine candidate in healthy children and adults in dengue-endemic regions: A randomized, placebo-controlled phase 2 study","volume":"213","author":"Sirivichayakul","year":"2016","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2022.01.016_b0085","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1080\/21645515.2020.1727697","article-title":"Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial","volume":"16","author":"Turner","year":"2020","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"10.1016\/j.vaccine.2022.01.016_b0090","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.vaccine.2019.11.061","article-title":"Safety and immunogenicity of a single dose of a tetravalent dengue vaccine with two different serotype-2 potencies in adults in Singapore: A phase 2, double-blind, randomised, controlled trial","volume":"38","author":"Tricou","year":"2020","journal-title":"Vaccine"},{"issue":"10234","key":"10.1016\/j.vaccine.2022.01.016_b0095","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(20)30556-0","article-title":"Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2\u201317 years: a randomised, placebo-controlled, phase 2 trial","volume":"395","author":"Tricou","year":"2020","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.vaccine.2022.01.016_b0100","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children and adolescents","volume":"381","author":"Biswal","year":"2019","journal-title":"N Engl J Med"},{"issue":"10234","key":"10.1016\/j.vaccine.2022.01.016_b0105","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(20)30414-1","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children aged 4\u201316 years: a randomised, placebo-controlled, phase 3 trial","volume":"395","author":"Biswal","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.01.016_b0110","first-page":"jiaa761","article-title":"Efficacy of a dengue vaccine candidate (TAK-003) in healthy children and adolescents two years after vaccination","author":"L\u00f3pez-Medina","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.01.016_b0115","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.3389\/fimmu.2019.02125","article-title":"Human T cell response to dengue virus infection","volume":"10","author":"Tian","year":"2019","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2022.01.016_b0120","doi-asserted-by":"crossref","first-page":"5405","DOI":"10.4049\/jimmunol.1001709","article-title":"CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination","volume":"185","author":"Yauch","year":"2010","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2022.01.016_b0125","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.4049\/jimmunol.0801974","article-title":"A protective role for dengue virus-specific CD8+ T cells","volume":"182","author":"Yauch","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2022.01.016_b0130","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1093\/infdis\/jir012","article-title":"Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection","volume":"203","author":"Hatch","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.01.016_b0135","doi-asserted-by":"crossref","first-page":"E2046","DOI":"10.1073\/pnas.1305227110","article-title":"Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells","volume":"110","author":"Weiskopf","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"31","key":"10.1016\/j.vaccine.2022.01.016_b0140","doi-asserted-by":"crossref","first-page":"E4256","DOI":"10.1073\/pnas.1505956112","article-title":"Dengue virus infection elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated with protective immunity","volume":"112","author":"Weiskopf","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.vaccine.2022.01.016_b0145","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1128\/JVI.02675-12","article-title":"Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection","volume":"87","author":"Rivino","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2022.01.016_b0150","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3389\/fimmu.2014.00093","article-title":"T cell immunity to infection with dengue virus in humans","volume":"5","author":"Weiskopf","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2022.01.016_b0155","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.3389\/fimmu.2019.01778","article-title":"Assessing the diversity and stability of cellular immunity generated in response to the candidate live-attenuated dengue virus vaccine TAK-003","volume":"10","author":"Waickman","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2022.01.016_b0160","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1038\/s41467-019-11634-7","article-title":"Dissecting the heterogeneity of DENV vaccine-elicited cellular immunity using single-cell RNA sequencing and metabolic profiling","volume":"10","author":"Waickman","year":"2019","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.vaccine.2022.01.016_b0165","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1093\/infdis\/jiv258","article-title":"CD8+ T-cell responses in flavivirus-naive individuals following immunization with a live-attenuated tetravalent dengue vaccine candidate","volume":"212","author":"Chu","year":"2015","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2022.01.016_b0170","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.vaccine.2008.10.086","article-title":"Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development","volume":"27","author":"Thomas","year":"2009","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2022.01.016_b0175","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J Roy Stat Soc Ser B"},{"issue":"18","key":"10.1016\/j.vaccine.2022.01.016_b0180","doi-asserted-by":"crossref","first-page":"10081","DOI":"10.1128\/JVI.00330-07","article-title":"Differential functional avidity of dengue virus-specific T-cell clones for variant peptides representing heterologous and previously encountered serotypes","volume":"81","author":"Imrie","year":"2007","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2022.01.016_b0185","doi-asserted-by":"crossref","first-page":"e0184732","DOI":"10.1371\/journal.pone.0184732","article-title":"Extrinsically derived TNF is primarily responsible for limiting antiviral CD8+ T cell response magnitude","volume":"12","author":"Quinn","year":"2017","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.vaccine.2022.01.016_b0190","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nri2274","article-title":"T-cell quality in memory and protection: implications for vaccine design","volume":"8","author":"Seder","year":"2008","journal-title":"Nat Rev Immunol"},{"issue":"45","key":"10.1016\/j.vaccine.2022.01.016_b0195","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1016\/j.vaccine.2008.08.019","article-title":"Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects","volume":"26","author":"Guy","year":"2008","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.vaccine.2022.01.016_b0200","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.vaccine.2022.01.016_b0205","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1093\/infdis\/jiv289","article-title":"Human CD8+ T-Cell Responses Against the 4 Dengue Virus Serotypes Are Associated With Distinct Patterns of Protein Targets","volume":"212","author":"Weiskopf","year":"2015","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2022.01.016_b0210","doi-asserted-by":"crossref","first-page":"e1742","DOI":"10.1371\/journal.pntd.0001742","article-title":"Primary vaccination with low dose live dengue 1 virus generates a proinflammatory, multifunctional T cell response in humans","volume":"6","author":"Lindow","year":"2012","journal-title":"PLoS Negl Trop Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22000408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22000408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:07:48Z","timestamp":1759403268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22000408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0264410X22000408"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.01.016","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of the cell-mediated immune response to Takeda\u2019s live-attenuated tetravalent dengue vaccine in adolescents participating in a phase 2 randomized controlled trial conducted in a dengue-endemic setting","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}